Saudi: Seven blood clots maybe linked to AstraZeneca

Saudi Arabia has recorded seven blood clots possibly associated with the Oxford-AstraZeneca COVID-19 vaccine, after receiving 34 complaints from vaccine recipients over side effects, local media reported, quoting the Saudi drug watchdog.

The Saudi Food and Drug Agency, however, said the immunological platelet deficiency and clotting syndrome associated with AstraZeneca vaccine has not been confirmed in any of these cases so far.

The Saudi FDA estimated the rate of occurrence of these symptoms in conjunction with the administration of the Oxford-AstraZeneca vaccine in the Kingdom is very rare.

It confirmed that the desired benefits from administering the vaccine still outweigh the potential risks according to the medical information approved for the vaccine, and that all vaccines approved in the Kingdom are of high safety.

The Saudi FDA recommended the vaccine recipient should consult the treating doctor or go to the nearest health center when any of the following symptoms appear and continue for more than three days after receiving AstraZeneca: dizziness, severe and persistent headache, nausea or vomiting, impaired vision, shortness of breath, severe pain in the chest or abdomen or coldness in the extremities, swelling of the legs, small blood spots under the skin at the injection site.


Gulf News

Related Articles

Back to top button